

Share capital information

Caravelle acquires an equity stake in Naturex

Press release

Avignon, 6 December 2012 - Naturex, the global leader in speciality plant-based natural ingredients, announces an equity investment by Groupe Caravelle, a diversified French industrial group with holdings in the pharmaceutical, industrial bodywork, mechanics and hotel sectors.

Natraceutical sells its equity stake

Caravelle's equity investment follows the sale by Natraceutical of its stake that represented 15.35% of the share capital and 8.27% of the voting rights on 5 December 2012.

Natraceutical, the Spanish group, had become a shareholder in December 2009 with a 38% stake after the Naturex acquired its Ingredients Division. Through this latter acquisition Naturex doubled in size and achieved a leadership position in its market.

Natraceutical had indicated its intention since 2011 to gradually divest its holdings in Naturex's share capital and in recent months has significantly reduced its stake.

Following this equity investment Naturex's shareholder structure is as follows:

Shareholders	Number of shares	Percentage of share capital	Percentage of voting rights
SGD	1,624,768	21.0%	20.4%
Caravelle	1,186,137	15.4%	14.9%
Free float	4,917,174	63.6%	64.6%
Total	7,728,079	100.0%	100.0%

All voting rights attached to shares from the conversion of the preferred shares sold by Natraceutical were transferred over to Caravelle.

* On a basis of 7,944,119 gross voting rights as at 5 December 2012

Caravelle, a new partner

This friendly acquisition fits within the development strategy of Caravelle that has clearly demonstrated its wish to participate in pursuing the development projects of Naturex Group in line with latter's strategy over the last 20 years.

"We welcome Caravelle Group's addition as a shareholder and will propose that Ms. H  l  ne Martel-Massignac, Caravelle's Chief Executive Officer, be appointed as a new member of Naturex's Board of Directors", commented Naturex's Chairman-CEO, Thierry Lambert. "This proposed nomination will be submitted to a vote at the next Shareholders Meeting".

You can receive all financial information of Naturex free of charge by signing up at: www.naturex.com

Naturex has been listed on NYSE Euronext Paris, Compartment B (Mid Caps), since October 1996.



Total number of shares comprising the share capital: 7,728,079
ISIN FR0000054694

Naturex is a component of the CAC Small and Gaïa indexes.

Naturex is eligible for "long only" Deferred Settlement Service (SRD).

Naturex established a Sponsored Level 1 American Depositary Receipt (ADR) program in the United States. Under this facility, Naturex's ADRs are traded over-the-counter in the United States under the symbol NTUXY.

SYMBOL: NRX - Reuters: NATU.PA - Bloomberg: NRX:FP - DR Symbol: NTUXY

About Naturex

Naturex is the global leader in speciality plant-based natural ingredients.

The Group is organised around three strategic markets (food & beverage, nutrition & health and personal care) and produces and markets speciality plant-based ingredients for the food, nutraceutical, pharmaceutical and cosmetic industries.

Naturex's head office is based in Avignon. The company employs more than 1,300 people with high-performance manufacturing operations across 15 sites in Europe (France, Italy, Spain, the United Kingdom, Switzerland, Poland) as well as in Morocco, the United States, Brazil, Australia and India. It also has a global presence through a dedicated network of sales offices in 21 countries (France, Italy, Spain, Morocco, the United Kingdom, Belgium, Germany, Poland, Russia, U.A.E., Thailand, Singapore, Japan, China, Korea, Australia, the United States, Canada, Brazil, Mexico and India).

Naturex's development is supported by positive underlying trends linked to the fast-growing demand for natural products and its capacity to provide manufacturers customised solutions to meet the requirements of their end consumers. The Group's strength lies in its positioning with specific products which constitute niche markets, supported by strong sourcing capacity and sustained research & development.

► Contacts

Thierry Lambert

Chairman and Chief Executive Officer

Tel: +33 (0)4 90 23 96 89

t.lambert@naturex.com

Carole Alexandre

Investor Relations

Tel: +33 (0)4 90 23 78 28

c.alexandre@naturex.com

Anne Catherine Bonjour

Actus Finance Press Relations

Tel: +33 (0)1 53 67 36 93

acbonjour@actus.fr